TABLE 1.

Per Capita Effects of Prevention of Cardiovascular Risk Factors on Health and Economic Outcomes of Americans Aged 51 or 52 Years

Hypothetical Scenario	% of Population Successfully Treated	Remaining Life Expectancy in Years	QALY-Adjusted Life Expectancy in Years	Lifetime Medical Spending,ab $	Value of Treatment,b $
Status Quo		30.19	15.53	170 013
Treatment effective for 10% of at-risk population
Diabetes	4.0	30.32	15.60	168 836	7 957
Hypertension	8.0	30.33	15.62	168 868	10 341
Obesity	6.8	30.25	15.56	169 511	3 673
Smoking	2.5	30.30	15.58	170 643	3 854
Treatment effective for 25% of at-risk population
Diabetes	10.8	30.53	15.71	166 298	21 305
Hypertension	20.8	30.58	15.78	166 953	27 614
Obesity	18.1	30.35	15.62	168 613	9 817
Smoking	7.0	30.44	15.63	171 214	8 447
Treatment effective for 50% of at-risk population
Diabetes	21.8	30.89	15.89	162 504	43 664
Hypertension	43.0	31.07	16.07	163 919	60 045
Obesity	35.2	30.52	15.70	167 708	18 820
Smoking	14.8	30.72	15.74	172 517	18 306
Treatment effective for 100% of at-risk population
Diabetes	43.0	31.55	16.23	155 190	85 120
Hypertension	84.8	31.93	16.58	158 392	117 015
Obesity	71.3	30.79	15.85	164 905	36 878
Smoking	28.0	31.15	15.91	174 479	33 287

Note. QALY = quality-adjusted life-year. Lifetime medical spending and QALYs were discounted at 3%. Value of treatment was computed relative to the status quo and calculated as the benefit from additional QALYs ($100 000 per year) minus the change in medical spending.

^aDerived from the medical component of the consumer price index published by the US Bureau of Labor Statistics.

^bSpending inflated to constant 2004 dollars.